CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data

Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)

[img] Text
294256.pdf - Published Version
Available under License Creative Commons Attribution.



(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy.

Item Type:Articles
Additional Information:Funding: This study was partly supported by grant PHRC-K 2017 ‘PHRC-K 17–187’ from the Programme Hospitalier de Recherche Clinique en Cancérologie, funded by the French Ministry of Health and the French Ligue Against Cancer.
Glasgow Author(s) Enlighten ID:Carty, Mrs Karen and Lewsley, Ms Liz-Anne and Kelly, Mrs Caroline and Glasspool, Dr Rosalind
Creator Roles:
Glasspool, R. M.Investigation, Resources, Writing – review and editing
Kelly, C.Investigation, Resources, Writing – review and editing
Lewsley, L.-A.Investigation, Resources, Writing – review and editing
Carty, K.Investigation, Resources, Writing – review and editing
Authors: Karamouza, E., Glasspool, R. M., Kelly, C., Lewsley, L.-A., Carty, K., Kristensen, G. B., Ethier, J.-L., Kagimura, T., Yanaihara, N., Cecere, S. C., You, B., Boere, I. A., Pujade-Lauraine, E., Ray-Coquard, I., Proust-Lima, C., and Paoletti, X.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Cancers
ISSN (Online):2072-6694
Copyright Holders:Copyright © 2023 by the authors
First Published:First published in Cancers 15(6):1823
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record